09 December 2021 : Database Analysis
Low Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Correlate of Immune Infiltrates in Breast Cancer
Weiwei Yi1ABCEF, Haiqing Shen2BC, Dexi Sun3BC, Yongchao Xu4BC, Yujie Feng1BC, Dongbing Li5BC, Caixia Wang1ABCEF*DOI: 10.12659/MSM.934522
Med Sci Monit 2021; 27:e934522
Table 3 Correlation between SLC26A4-AS1 expression and clinical characteristics in patients with breast cancer (logistic regression).
| Characteristics | Total (N) | Odds ratio (OR) | P value |
|---|---|---|---|
| T stage (T2 & T3 & T4 vs T1) | 1080 | 1.035 (0.787–1.360) | 0.807 |
| N stage (N1 & N2 & N3 vs N0) | 1064 | 0.866 (0.680–1.101) | 0.240 |
| M stage (M1 vs M0) | 922 | 0.822 (0.328–2.004) | 0.666 |
| Pathologic stage (Stage III & Stage IV vs Stage I & Stage II) | 1060 | 0.908 (0.686–1.201) | 0.499 |
| Race (Black or African American & White vs Asian) | 994 | 1.066 (0.631–1.802) | 0.809 |
| Age (>60 vs ≤60) | 1083 | 0.655 (0.514–0.833) | <0.001 |
| Histological type (Infiltrating Lobular Carcinoma vs Infiltrating Ductal Carcinoma) | 977 | 0.976 (0.717–1.329) | 0.878 |
| PR status (Indeterminate vs Negative) | 346 | 0.701 (0.083–5.902) | 0.725 |
| ER status (Positive & Indeterminate vs Negative) | 1035 | 0.503 (0.373–0.675) | <0.001 |
| HER2 status (Indeterminate & Positive vs Negative) | 727 | 1.181 (0.836–1.671) | 0.346 |
| PAM50 (LumA & LumB & Her2 vs Basal) | 1043 | 0.312 (0.221–0.435) | <0.001 |
| Menopause status (Post vs Pre & Peri) | 972 | 0.597 (0.448–0.793) | <0.001 |
| Anatomic neoplasm subdivisions (Right vs Left) | 1083 | 0.859 (0.677–1.091) | 0.213 |
| Radiation therapy (Yes vs No) | 987 | 1.083 (0.842–1.393) | 0.533 |